This course will describe the various pharmacodynamic (PD), pharmacokinetic (PK) and toxicology studies that are required for an investigational drug application (IND) to the food and drug administration (FDA). It will cover key concepts for the development of small and large molecules, with an emphasis on the 505(b)(1) regulatory submission route for new chemical entities (NCE) and new biological entities (NBE)
Bringing a new therapy to market is costly and evolving market pressures are changing the focus of the drug development industry. With an average investment of $2.6 billion dollars and sometimes more than a decade in development, rarely is the path from discovery to the patient a straight line. Multiple unexpected challenges arise, from regulatory hurdles to new safety concerns. Given these increasing pressures, understanding how and when to plan a preclinical IND-enabling program is an integral part of meeting specific milestones necessary for a timely and efficient IND submission. This seminar will review the path from lead candidate selection to IND preparation and the necessary studies required for a successful submission.
Course Objectives:
After this session you should be able to identify the types of regulatory submissions required to conduct human trials in the US, the studies required to submit an IND, the various safety studies required for different phases of clinical development and identify the essential PK/PD studies required to support toxicological segments.
Course Outline:
Topics covered include:
• Drug development regulatory bodies
• IND sections
• Pharmacology
• DMPK
• Toxicology
• Submission process
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Regulatory Affairs
• Quality Assurance
• Clinical Trial Personnel
• Pharmacovigilance
• Project Management
• Regulatory Operations
• Medical and Technical writers
• Professionals preparing INDs and other submissions
• IT Professionals
Preclinical scientists, academics with clinical trial interests and those generally interested in drug development will benefit a lot from this session.
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Providing DMFs in eCTD format
Get Instant Access 90 Minutes View Program |
QSR-Compliant Equipment Control & Validation of Processes in the Manufacturing Environment
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry